{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-017924","form_type":"8-K","ticker":"SABS","cik":"0001833214","company_name":"SAB Biotherapeutics, Inc.","filed_at":"2023-06-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.002054+00:00","generated_at":"2026-06-13T20:15:56.537336+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"SAB Biotherapeutics reports positive GLP tox study for SAB-142; IND submission planned","bullets":["SAB-142 well tolerated in GLP tox study; NOAEL 10 mg/kg (highest dose).","SAB-142 modulates key T-cell subsets similarly to rabbit ATG in vivo, confirming mechanism.","Plans to submit IND for SAB-142 to FDA and initiate Phase 1 trial in coming months.","Over 8.4M people affected by T1D worldwide; only one disease-modifying treatment available."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-017924","json":"https://secwatch.observer/filing/0001437749-23-017924.json","markdown":"https://secwatch.observer/filing/0001437749-23-017924.md","text":"https://secwatch.observer/filing/0001437749-23-017924.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833214/000143774923017924/0001437749-23-017924-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833214/000143774923017924/sabs20230619_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T20:15:56.537336+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}